CELLECTIS S A CLLS
SPON ADS · ADR · CUSIP 15117K103
Biopharmaceutical company
- SectorHealth care
- IndustryBiological Products, (No Diagnostic Substances)
- HeadquartersFrance, France
- Founded1999
- Websitecellectis.com
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $3.00. Options: 1 managers hold calls ($38.4k notional), 0 hold puts (—).
Trends to Q2 2026
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 50 |
| Q4 2022 | 41 |
| Q1 2023 | 35 |
| Q2 2023 | 37 |
| Q3 2023 | 32 |
| Q4 2023 | 35 |
| Q1 2024 | 32 |
| Q2 2024 | 28 |
| Q3 2024 | 28 |
| Q4 2024 | 30 |
| Q1 2025 | 28 |
| Q2 2025 | 25 |
| Q3 2025 | 28 |
| Q4 2025 | 34 |
| Q1 2026 | 32 |
| Q2 2026 | 27 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q3 2024 | 7 | 7 |
| Q4 2024 | 11 | 10 |
| Q1 2025 | 8 | 13 |
| Q2 2025 | 8 | 14 |
| Q3 2025 | 13 | 9 |
| Q4 2025 | 18 | 11 |
| Q1 2026 | 7 | 19 |
| Q2 2026 | 5 | 17 |
Calls vs puts
Options held, notional value, last 4 quarters. P/C = puts ÷ calls
Numbers
| Quarter | Calls | Puts | P/C |
|---|---|---|---|
| Q3 2025 | $238.3k | $1.1k | 0.00 |
| Q4 2025 | $62.9k | $2.9k | 0.05 |
| Q1 2026 | $41.8k | $634 | 0.02 |
| Q2 2026 | $38.4k | $0 | 0.00 |
Biggest buyers
| UBS Group AG | Added | +4.2k |
| ROYAL BANK OF CANADA | New | +1.6k |
| LPL Financial LLC | Added | +70 |
| JONES FINANCIAL COMPANIES LLLP | New | +50 |
| Caitong International Asset Management Co., Ltd | New | +49 |
Biggest sellers
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | Reduced | -533.7k |
| BlackRock, Inc. | Reduced | -116.1k |
| CITADEL ADVISORS LLC | Sold out | -44.3k |
| MARSHALL WACE, LLP | Sold out | -41.1k |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | Reduced | -15.5k |
| Lido Advisors, LLC | Sold out | -10.1k |
| XTX Topco Ltd | Reduced | -4.0k |
| Long Focus Capital Management, LLC | Reduced | -2.2k |
| Tower Research Capital LLC (TRC) | Sold out | -1.8k |
| MORGAN STANLEY | Reduced | -1.3k |
Biggest calls
| GROUP ONE TRADING LLC | Reduced | $38.4k12.8k shares |
Biggest puts
| None |
Options at notional value: the value of the shares the contracts control, as filers report them, not what the options cost. Not included in the holders, shares or buying above.
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
ASTRAZENECA PLC
13D · may seek influence
filed 2025-01-24
Stated purposeItem 4 of the Schedule 13D is hereby amended and supplemented to add the following: "On May 7, 2024, AstraZeneca announced the successful completion of the Additional Investment pursuant to which AZ Holdings BV received 10,000,000 series A convertible preferred shares of the Issuer and 18,000,000 series B convertible shares of the Issuer, each at a price of $5.00 per convertible preferred share, as contemplated and described in more detail elsewhere in the Schedule 13D. On January 15, 2025, the Issuer filed a Registration Statement on Form F-3 (File No. 333-284302) (the "Registration Statement"), which was declared effective by the Securities and Exchange Commission on January 23, 2025, to register the resale of Ordinary Shares (including in the form of American Depositary Shares) issuab… Full filing |
44.0% |
Bpifrance Participations SA
13D · may seek influence
-2.0 pts · filed 2025-12-12
Stated purposeItem 4 of the Schedule 13D is hereby amended and supplemented as follows: This Amendment is being filed to reflect a decrease in the Reporting Persons percentage ownership of the Issuer's Ordinary Shares and voting rights, which resulted from an increase in the number of Ordinary Shares and voting rights outstanding since the filing of Amendment No. 5 to the Schedule 13D and is not due to any transactions in the Ordinary Shares by the Reporting Persons. All of the Ordinary Shares that are held of record by the Reporting Persons as reported herein were acquired for investment purposes. The Reporting Persons retain the right to change their investment intent, from time to time to acquire additional Ordinary Shares or other securities of the Issuer, or to sell or otherwise dispose of all or… Full filing |
11.1% |
Insider purchases and sales since 1 Apr 2026
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
None reported since 1 Apr 2026.
Holders, Q2 2026
| Manager | Shares | Change |
|---|---|---|
| B Group, Inc. 5.59% of their portfolio | 3.3m $9.8m | Unchanged |
| Long Focus Capital Management, LLC 0.34% of their portfolio | 2.7m $8.2m | Reduced -2.2k |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 0.00% of their portfolio | 2.6m $7.9m | Reduced -533.7k |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 0.00% of their portfolio | 226.9k $681.0k | Unchanged |
| BlackRock, Inc. 0.00% of their portfolio | 225.4k $676.3k | Reduced -116.1k |
| MORGAN STANLEY 0.00% of their portfolio | 85.5k $256.4k | Reduced -1.3k |
| LPL Financial LLC 0.00% of their portfolio | 84.4k $253.2k | Added +70 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.00% of their portfolio | 50.5k $151.4k | Reduced -15.5k |
| BNP PARIBAS FINANCIAL MARKETS 0.00% of their portfolio | 40.1k $120.3k | Reduced -900 |
| UBS Group AG 0.00% of their portfolio | 33.9k $101.8k | Added +4.2k |
| Delaney Dennis R 0.02% of their portfolio | 24.0k $72.0k | Unchanged |
| RHUMBLINE ADVISERS 0.00% of their portfolio | 14.3k $43.0k | Reduced -757 |
| XTX Topco Ltd 0.00% of their portfolio | 12.3k $36.8k | Reduced -4.0k |
| HARBOUR INVESTMENTS, INC. 0.00% of their portfolio | 4.5k $13.5k | Unchanged |
| NATIONAL BANK OF CANADA /FI/ 0.00% of their portfolio | 3.6k $10.8k | Unchanged |
| WELLS FARGO & COMPANY/MN 0.00% of their portfolio | 3.1k $9.4k | Unchanged |
| ROYAL BANK OF CANADA 0.00% of their portfolio | 1.6k $5.0k | New |
| Atlantic Union Bankshares Corp 0.00% of their portfolio | 1.5k $4.5k | Unchanged |
| Allworth Financial LP 0.00% of their portfolio | 500 $1.5k | Unchanged |
| POM Investment Strategies, LLC 0.00% of their portfolio | 495 $1.5k | Unchanged |
| GAMMA Investing LLC 0.00% of their portfolio | 463 $1.4k | Reduced -271 |
| OSAIC HOLDINGS, INC. 0.00% of their portfolio | 100 $300 | Unchanged |
| Larson Financial Group LLC 0.00% of their portfolio | 75 $225 | Unchanged |
| JONES FINANCIAL COMPANIES LLLP 0.00% of their portfolio | 50 $142 | New |
| Caitong International Asset Management Co., Ltd 0.00% of their portfolio | 49 $147 | New |
| EverSource Wealth Advisors, LLC 0.00% of their portfolio | 13 $39 | Unchanged |
| Inspire Investing, LLC 0.00% of their portfolio | 6 $18 | Unchanged |